[Bathmotropic effect of panangin and strophanthin in patients with extrasystole].
The antiarrhythmic effect of Panangine and Strophantin was studied by way of rhythmography in patients with extrasystole of different etiology. The strophantin (0.25 mg) an Panangine (2 vials intravenously) tests, and therapeutic courses of Panagine (2 coated tablets 3 times a day for 5--7 days) or of Strophantin (0.25 mg) with Panagine (2 vials intravenously) for 7--10 days were conducted. A course of Strophantin with Panangine was given only to those patient who did not increase the number of their extrasystoles after the Strophantin test. Such a course resulted in the most striking antiarrhythmic effect (60.3% of the patients).
D000284:Administration, Oral; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001224:Aspartic Acid / Q000031:analogs & derivatives*; D005117:Cardiac Complexes, Premature / Q000188:drug therapy* / Q000209:etiology; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D006334:Heart Function Tests; D006801:Humans; D007275:Injections, Intravenous; D011195:Potassium Magnesium Aspartate / Q000008:administration & dosage* / Q000627:therapeutic use; D013328:Strophanthins / Q000008:administration & dosage* / Q000627:therapeutic use
D000889:Anti-Arrhythmia Agents; D013328:Strophanthins; D001224:Aspartic Acid; D011195:Potassium Magnesium Aspartate
Batmotropnoe deĭstvie panangina i strofantina u bol'nykh s ékstrasistolieĭ